Hanall Biopharma (009420) — Strategic Asset Allocation Index
Hanall Biopharma (009420) has a Strategic Asset Allocation Index of 11.4% as of December 2022. Strategic assets (PP&E of ₩19.13 Billion plus long-term investments of ₩-) total ₩19.13 Billion, measured against net assets of ₩168.26 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check 009420 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Hanall Biopharma Strategic Asset Allocation Index (2011–2022)
This chart shows how Hanall Biopharma's Strategic Asset Allocation Index has evolved across 12 annual periods from 2011 to 2022. As of December 2022, the index stands at 11.4%, representing strategic assets of ₩19.13 Billion against net assets of ₩168.26 Billion KRW. See 009420 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Hanall Biopharma (2011–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Hanall Biopharma from 2011 to 2022, covering 12 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 009420 company net worth.
| Year | SAAI | Strategic Assets (KRW) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 11.4% | ₩19.13 Billion | ₩19.13 Billion | ₩- | ₩168.26 Billion | ▼ -0.3 pp |
| 2021 | 11.6% | ₩19.04 Billion | ₩19.04 Billion | ₩- | ₩163.49 Billion | ▲ +3.1 pp |
| 2020 | 8.5% | ₩15.48 Billion | ₩15.48 Billion | ₩- | ₩181.27 Billion | ▼ -14.9 pp |
| 2019 | 23.4% | ₩32.87 Billion | ₩14.94 Billion | ₩17.93 Billion | ₩140.42 Billion | ▲ +6.4 pp |
| 2018 | 17.0% | ₩19.91 Billion | ₩13.77 Billion | ₩6.14 Billion | ₩116.92 Billion | ▲ +3.4 pp |
| 2017 | 13.6% | ₩15.14 Billion | ₩13.38 Billion | ₩1.76 Billion | ₩111.20 Billion | ▼ -1.3 pp |
| 2016 | 14.9% | ₩15.56 Billion | ₩13.78 Billion | ₩1.78 Billion | ₩104.36 Billion | ▲ +1.0 pp |
| 2015 | 13.9% | ₩13.24 Billion | ₩12.18 Billion | ₩1.06 Billion | ₩95.22 Billion | ▼ -12.6 pp |
| 2014 | 26.5% | ₩12.12 Billion | ₩11.86 Billion | ₩264.91 Million | ₩45.81 Billion | ▲ +4.6 pp |
| 2013 | 21.8% | ₩13.01 Billion | ₩12.20 Billion | ₩805.28 Million | ₩59.63 Billion | ▲ +8.5 pp |
| 2012 | 13.3% | ₩10.50 Billion | ₩10.50 Billion | ₩- | ₩78.67 Billion | ▼ -5.9 pp |
| 2011 | 19.3% | ₩9.78 Billion | ₩9.78 Billion | ₩- | ₩50.70 Billion | — |